Natco Pharma hosts investor meet in Mumbai and Hong Kong on August 27

0 min read | Published on 24 Aug 2026, 09:08 PM |Updated on 24 Aug 2026, 09:43 PM

Reviewed by

Riya DScanX News Team

Key Highlights

Natco Pharma to host investor meetings on August 27, 2026. Sessions scheduled in Mumbai and Hong Kong. Organized by Nuvama Wealth Management and ICICI Securities.

*this image is generated using AI for illustrative purposes only.

Natco Pharma will host investor meetings on August 27, 2026, in Mumbai and Hong Kong. The sessions are organized by Nuvama Wealth Management Limited and ICICI Securities Limited.

Meeting Schedule

The company’s officials will participate in group meetings across two locations. The schedule is subject to change due to exigencies.

Location	Date	Time
Mumbai	August 27, 2026	9:00 am to 6:00 pm
Hong Kong	August 27-28, 2026	9:00 am-5:00 pm (Aug 27); 9:00 am-1:00 pm (Aug 28)

Disclosure Details

The interactions fall under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No unpublished price-sensitive information (UPSI) will be discussed. The latest investor presentation is available on the company website.

Historical Stock Returns for Natco Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.19%	-2.11%	-8.09%	-1.00%	+0.32%	-2.03%

What strategic updates regarding Natco Pharma's pipeline or international expansion plans are investors likely to seek during these meetings?

How might the presence of both domestic (Nuvama) and international (ICICI Securities) organizers signal Natco's strategy to attract foreign institutional investors?

Could the dual-location schedule indicate a targeted effort to address specific regulatory or market concerns in Asian markets compared to the Indian domestic market?

Natco Pharma

View Company Insights

View All News

Natco Pharma receives Form 483 with 4 findings at Visakhapatnam FDF facility

0 min read | Published on 21 Aug 2026, 05:43 PM |Updated on 21 Aug 2026, 05:43 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Natco Pharma received a Form 483 from the USFDA following an inspection at its Visakhapatnam finished dosage form facility. The Form 483 contains 4 observations raised by USFDA investigators. A Form 483 is issued when inspectors note conditions that may indicate potential regulatory violations. The document requires the company to respond with corrective action plans.

*this image is generated using AI for illustrative purposes only.

Natco Pharma received a Form 483 with 4 observations from the US Food and Drug Administration following an inspection at its Visakhapatnam finished dosage form facility.

USFDA inspection outcome

A Form 483 is issued by the USFDA when investigators observe conditions or practices that may indicate violations of the Food Drug and Cosmetic Act during an inspection. The receipt of such a document does not constitute a final agency determination of non-compliance, but requires the inspected facility to respond with corrective action plans.

Key details of the inspection

Parameter	Details
Company	Natco Pharma
Facility location	Visakhapatnam
Facility type	Finished dosage form (FDF)
Regulatory document	Form 483
Number of findings	4

The Visakhapatnam FDF facility is subject to USFDA oversight as part of the regulatory requirements for pharmaceutical manufacturers supplying to the US market. Companies typically respond to Form 483 observations within 15 business days, outlining corrective and preventive actions to address the findings raised by investigators.

Historical Stock Returns for Natco Pharma